608.05(c) Submissions of Biological Sequence Listings [R-07.2022]

Applications disclosing nucleotide and/or amino acid sequences, as defined in 37 CFR 1.821(a) for applications filed before July 1, 2022 or as defined in 37 CFR 1.831(b) for applications filed on or after July 1, 2022, are required to provide the biological sequence information in a sequence listing.

For applications filed before July 1, 2022, the sequence listing can be a “Sequence Listing” (as an ACSII plain text file in compliance with 37 CFR 1.821–1.824) submission must be submitted via the USPTO patent electronic filing system or on read-only optical disc. See MPEP §§ 2420et seq. for detailed information.

For applications filed on or after July 1, 2022, the sequence listing must be a “Sequence Listing XML” (as an XML file in compliance with 37 CFR 1.831–1.834) submission can be submitted via the USPTO patent electronic filing system or on read-only optical disc. See MPEP §§ 2412–2419 for detailed information.